Fewer CV events for heart failure with reduced ejection fraction
PHILADELPHIA -- Heart failure patients with reduced ejection fraction but no diabetes appear to benefit significantly when the diabetes drug dapagliflozin (Farxiga) is added to their treatment regimens, researchers reported here.